{"id":"epirubicin-cyclophosphamide-and-docetaxel","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Cardiotoxicity (epirubicin-related)"},{"rate":null,"effect":"Peripheral neuropathy (docetaxel-related)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Epirubicin is a topoisomerase II inhibitor that intercalates into DNA and prevents strand separation. Cyclophosphamide is an alkylating agent that cross-links DNA strands. Docetaxel is a microtubule stabilizer that prevents microtubule depolymerization, blocking cell division. Together, these three drugs attack cancer cells through complementary mechanisms of action.","oneSentence":"This is a combination chemotherapy regimen that uses three cytotoxic agents to damage cancer cell DNA and inhibit cell division, used in breast cancer treatment.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:11:07.445Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Breast cancer (neoadjuvant and adjuvant treatment)"}]},"trialDetails":[{"nctId":"NCT00911911","phase":"NA","title":"Proteomic Signature in Breast Cancer: Correlation With Tumor Response to Neo-adjuvant Chemotherapy","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2007-02-22","conditions":"Breast Cancer","enrollment":66},{"nctId":"NCT07441460","phase":"PHASE3","title":"A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2026-03-07","conditions":"Resectable HER2-positive Breast Cancer","enrollment":1800},{"nctId":"NCT07162051","phase":"PHASE2","title":"A Study on the Use of Fluzoparib Combined With Chemotherapy for Neoadjuvant Treatment of HRD-positive, HR+/HER2- Breast Cancer","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2023-03-03","conditions":"HR+/HER2- Early Breast Cancer","enrollment":28},{"nctId":"NCT06291064","phase":"PHASE2","title":"Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-03-18","conditions":"Triple Negative Breast Cancer","enrollment":85},{"nctId":"NCT07410234","phase":"PHASE2","title":"Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity to Neoadjuvant Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-02-21","conditions":"Breast Cancer","enrollment":110},{"nctId":"NCT02624973","phase":"PHASE2","title":"PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Haukeland University Hospital","startDate":"2016-04-15","conditions":"Breast Cancer","enrollment":200},{"nctId":"NCT06009627","phase":"PHASE2, PHASE3","title":"Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients","status":"COMPLETED","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-04-11","conditions":"Breast Cancer","enrollment":119},{"nctId":"NCT07378306","phase":"PHASE2","title":"FMD and Neoadjuvant Chemo-immunotherapy in TNBC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-01","conditions":"Breast Cancer","enrollment":80},{"nctId":"NCT04290793","phase":"PHASE2, PHASE3","title":"Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2020-03-01","conditions":"Breast Cancer","enrollment":113},{"nctId":"NCT04872985","phase":"PHASE2","title":"Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2021-04-20","conditions":"Breast Cancer, Hormone-receptor Positive Breast Cancer","enrollment":140},{"nctId":"NCT07317778","phase":"PHASE2","title":"Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-02-15","conditions":"Breast Cancer Early Stage Breast Cancer (Stage 1-3), HR Positive/HER2 Low Breast Cancer","enrollment":249},{"nctId":"NCT06107673","phase":"PHASE2","title":"Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2023-09-30","conditions":"Breast Cancer","enrollment":144},{"nctId":"NCT01358877","phase":"PHASE3","title":"A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-11-08","conditions":"Breast Cancer","enrollment":4804},{"nctId":"NCT04193059","phase":"PHASE3","title":"Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fudan University","startDate":"2019-12-20","conditions":"Breast Cancer","enrollment":1560},{"nctId":"NCT01710176","phase":"PHASE3","title":"Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy","status":"COMPLETED","sponsor":"Italian Sarcoma Group","startDate":"2011-06-01","conditions":"Localized High-risk Soft Tissue Sarcomas of the Extremities and Trunk Wall in Adults","enrollment":550},{"nctId":"NCT00872625","phase":"PHASE1","title":"Radiation Therapy and Docetaxel Followed by Standard Therapy in Treating Women With Breast Cancer","status":"COMPLETED","sponsor":"Centre Antoine Lacassagne","startDate":"2007-04","conditions":"Breast Cancer","enrollment":26},{"nctId":"NCT05900206","phase":"PHASE2","title":"Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"Karolinska University Hospital","startDate":"2023-10-26","conditions":"Breast Cancer","enrollment":370},{"nctId":"NCT05582499","phase":"PHASE2","title":"Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-11-01","conditions":"Breast Neoplasm, Breast Cancer, Breast Tumors","enrollment":716},{"nctId":"NCT01354522","phase":"PHASE3","title":"TAC Versus TCX as Adjuvant Treatment for High-risk Her2-Negative Breast Cancer","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2011-05","conditions":"Breast Cancer","enrollment":204},{"nctId":"NCT03201861","phase":"PHASE3","title":"Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2017-07-27","conditions":"Tubular Breast Cancer, Mucinous Breast Cancer, Invasive Duct Carcinoma of Breast","enrollment":762},{"nctId":"NCT01779206","phase":"PHASE2, PHASE3","title":"ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer","status":"COMPLETED","sponsor":"West German Study Group","startDate":"2012-05","conditions":"Breast Cancer","enrollment":4936},{"nctId":"NCT06768931","phase":"PHASE2","title":"Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-12-30","conditions":"Breast Cancer, Triple Negative Breast Cancer (TNBC), Early Stage Breast Cancer","enrollment":192},{"nctId":"NCT05296746","phase":"PHASE2","title":"Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer","status":"RECRUITING","sponsor":"SOLTI Breast Cancer Research Group","startDate":"2022-05-03","conditions":"Breast Cancer Stage II","enrollment":1100},{"nctId":"NCT06795503","phase":"PHASE3","title":"Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-02","conditions":"Triple-negative Breast Cancer","enrollment":1462},{"nctId":"NCT02299999","phase":"PHASE2","title":"SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2014-04-07","conditions":"Metastatic Breast Cancer","enrollment":1460},{"nctId":"NCT00798070","phase":"PHASE3","title":"Panther: A Study Comparing Biweekly and Tailored EC-T Versus Three Weekly FEC-T in Breast Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Karolinska University Hospital","startDate":"2007-02","conditions":"Breast Cancer","enrollment":2017},{"nctId":"NCT05165225","phase":"PHASE2","title":"Phase II Neoadjuvant Pyrotinib Combined with Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2021-07-13","conditions":"Breast Cancer, HER2-low-expressing Breast Cancer, Hormone Receptor-positive Breast Cancer","enrollment":48},{"nctId":"NCT02339532","phase":"PHASE2","title":"Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2015-01","conditions":"Breast Cancer","enrollment":86},{"nctId":"NCT03013504","phase":"PHASE3","title":"A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients","status":"COMPLETED","sponsor":"Prestige Biopharma Limited","startDate":"2018-02-19","conditions":"HER2 Positive Breast Cancer","enrollment":503},{"nctId":"NCT06470633","phase":"PHASE2","title":"To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-08-01","conditions":"Breast Cancer, HR+/HER2- Breast Cancer","enrollment":29},{"nctId":"NCT05474690","phase":"PHASE3","title":"A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer","status":"WITHDRAWN","sponsor":"Henan Cancer Hospital","startDate":"2022-05-11","conditions":"Breast Cancer, HER2-positive Breast Cancer","enrollment":""},{"nctId":"NCT00630032","phase":"PHASE3","title":"Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2007-09","conditions":"Breast Cancer","enrollment":762},{"nctId":"NCT02641847","phase":"PHASE2, PHASE3","title":"TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fudan University","startDate":"2016-01","conditions":"Triple Negative Breast Cancer, Breast Cancer","enrollment":503},{"nctId":"NCT03609047","phase":"PHASE2","title":"Adjuvant Palbociclib in Elderly Patients With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2019-06-14","conditions":"Breast Cancer Stage II, Breast Cancer Stage III","enrollment":366},{"nctId":"NCT05978648","phase":"PHASE2","title":"Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy","status":"RECRUITING","sponsor":"wang shusen","startDate":"2023-09-20","conditions":"Breast Neoplasms","enrollment":116},{"nctId":"NCT04172259","phase":"PHASE2","title":"ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2019-01-10","conditions":"Breast Cancer, Neoadjuvant Chemotherapy","enrollment":156},{"nctId":"NCT05985187","phase":"PHASE3","title":"Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer.","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-10-20","conditions":"HER2-positive Breast Cancer","enrollment":412},{"nctId":"NCT05931042","phase":"","title":"Neoadjuvant Therapy With Trastuzumab and Chemotherapy and the Resultant Pathologic Complete Response Observed in HER2 Positive Breast Cancer;a Systematic Review","status":"COMPLETED","sponsor":"Rawalpindi Medical College","startDate":"2023-06-01","conditions":"HER2+ Breast Cancer","enrollment":1209},{"nctId":"NCT05883852","phase":"PHASE3","title":"EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-06-07","conditions":"HER2 Positive Early Breast Cancer","enrollment":1406},{"nctId":"NCT05901428","phase":"PHASE3","title":"TCb vs EC-T in High Risk ER+/HER2- Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-06-01","conditions":"Hormone Receptor Positive HER-2 Negative Breast Cancer","enrollment":1736},{"nctId":"NCT05871918","phase":"PHASE3","title":"A Multicenter, Randomized, Open, Phase III Trial of ddEC-THPvs Evaluating the Efficacy and Safety of TCHP Neoadjuvant Therapy for HER2-positive Breast Cancer","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2022-10-08","conditions":"HER-2 Positive Breast Cancer","enrollment":832},{"nctId":"NCT02586025","phase":"PHASE3","title":"Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-03-14","conditions":"Breast Cancer","enrollment":329},{"nctId":"NCT00432172","phase":"PHASE2","title":"Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients","status":"COMPLETED","sponsor":"Spanish Breast Cancer Research Group","startDate":"2007-04-24","conditions":"Breast Cancer","enrollment":189},{"nctId":"NCT00841828","phase":"PHASE2","title":"Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients","status":"COMPLETED","sponsor":"Spanish Breast Cancer Research Group","startDate":"2009-02","conditions":"Breast Cancer","enrollment":102},{"nctId":"NCT00129935","phase":"PHASE3","title":"EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer","status":"COMPLETED","sponsor":"Spanish Breast Cancer Research Group","startDate":"2004-02","conditions":"Breast Cancer","enrollment":1384},{"nctId":"NCT00773695","phase":"PHASE2","title":"A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-11-07","conditions":"Breast Cancer","enrollment":150},{"nctId":"NCT05656079","phase":"NA","title":"To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study","status":"UNKNOWN","sponsor":"Shanghai Pudong Hospital","startDate":"2021-07-01","conditions":"Breast Cancer","enrollment":204},{"nctId":"NCT05636644","phase":"","title":"Neoadjuvant Effect of Albumin Binding Paclitaxel Compared With Common Paclitaxel in Breast Cancer：an Observational Single Center Study of Clinical Efficacy in Adjuvant Chemotherapy","status":"UNKNOWN","sponsor":"Mei Zhang","startDate":"2022-11-04","conditions":"Breast Cancer","enrollment":112},{"nctId":"NCT01779050","phase":"PHASE2","title":"Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2013-12-19","conditions":"Breast Neoplasms","enrollment":7},{"nctId":"NCT02549677","phase":"PHASE4","title":"Epirubicin Versus Docetaxel Plus Cyclophosphamide in Lymph Node Negative, ER-positive, Her2-negative Breast Cancer","status":"COMPLETED","sponsor":"Ruijin Hospital","startDate":"2015-10","conditions":"Breast Neoplasms","enrollment":294},{"nctId":"NCT03154749","phase":"PHASE2","title":"DCb (Docetaxel/Carboplatin) Versus EC-D (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer","status":"COMPLETED","sponsor":"Guangdong Provincial People's Hospital","startDate":"2016-09-01","conditions":"Triple-Negative Breast Cancer","enrollment":93},{"nctId":"NCT05483439","phase":"PHASE2","title":"A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer","status":"UNKNOWN","sponsor":"Shengjing Hospital","startDate":"2021-10-20","conditions":"Stage II-III Breast Cancer","enrollment":100},{"nctId":"NCT05420454","phase":"PHASE4","title":"A Study for the Neoadjuvant Treatment of Breast Cancer","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-07-10","conditions":"Breast Cancer","enrollment":1576},{"nctId":"NCT05420467","phase":"PHASE4","title":"A Study for the Adjuvant Treatment of Breast Cancer","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-07-10","conditions":"Breast Cancer","enrollment":2413},{"nctId":"NCT01966471","phase":"PHASE3","title":"A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-01-31","conditions":"Breast Cancer","enrollment":1846},{"nctId":"NCT05400993","phase":"PHASE2","title":"Clinical Study of Chidamide Combined With Chemotherapy in Neoadjuvant Treatment of HR+/ HER2-BC","status":"UNKNOWN","sponsor":"Shengjing Hospital","startDate":"2022-05-23","conditions":"Breast Cancer","enrollment":59},{"nctId":"NCT02897050","phase":"PHASE2","title":"Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer","status":"SUSPENDED","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2016-09","conditions":"Breast Cancer","enrollment":170},{"nctId":"NCT04836156","phase":"PHASE1, PHASE2","title":"Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer Patients","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2021-04-02","conditions":"HER2-negative Early Breast Cancer","enrollment":46},{"nctId":"NCT05287308","phase":"NA","title":"Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study","status":"NOT_YET_RECRUITING","sponsor":"Chinese Academy of Medical Sciences","startDate":"2022-03","conditions":"Breast Cancer","enrollment":500},{"nctId":"NCT05251766","phase":"PHASE1","title":"Nab-paclitaxel Compared With Docetaxel in the Neoadjuvant Chemotherapy Breast Cancer","status":"UNKNOWN","sponsor":"Xuli Meng","startDate":"2022-04-20","conditions":"Breast Cancer, Chemotherapy Effect","enrollment":30},{"nctId":"NCT03243838","phase":"PHASE2","title":"Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"Guangdong Provincial People's Hospital","startDate":"2018-08-01","conditions":"Triple-Negative Breast Cancer","enrollment":31},{"nctId":"NCT04929548","phase":"PHASE4","title":"Exploratory Study of Neoadjuvant Treatment of HER2-positive Breast Cancer With Py in Combination With HP","status":"NOT_YET_RECRUITING","sponsor":"Wuhan University","startDate":"2022-01-05","conditions":"Breast Cancer","enrollment":20},{"nctId":"NCT05131893","phase":"","title":"Neoadjuvant Treatment of Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Oncology, Hungary","startDate":"2022-03","conditions":"Breast Cancer","enrollment":300},{"nctId":"NCT02468739","phase":"PHASE3","title":"Effect of GM1 in Prevention of Taxanes Induced Neurotoxicity in Operable Breast Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2015-05","conditions":"Breast Cancer","enrollment":206},{"nctId":"NCT00464646","phase":"PHASE2","title":"Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer","status":"COMPLETED","sponsor":"NSABP Foundation Inc","startDate":"2007-05","conditions":"Breast Cancer","enrollment":105},{"nctId":"NCT03894007","phase":"PHASE2","title":"Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer","status":"TERMINATED","sponsor":"Renske Altena","startDate":"2019-05-23","conditions":"Early-stage Breast Cancer, HER2-positive Breast Cancer","enrollment":6},{"nctId":"NCT02132949","phase":"PHASE2","title":"A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-07-14","conditions":"Breast Cancer","enrollment":401},{"nctId":"NCT04576143","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-09-20","conditions":"HER2-negative Breast Cancer, Neoadjuvant Chemotherapy","enrollment":260},{"nctId":"NCT04137640","phase":"PHASE4","title":"Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Shengjing Hospital","startDate":"2021-07-19","conditions":"Breast Cancer","enrollment":152},{"nctId":"NCT04717531","phase":"PHASE2","title":"Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2021-06-03","conditions":"Breast Cancer","enrollment":60},{"nctId":"NCT01220128","phase":"PHASE2","title":"Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2011-04-11","conditions":"Neoplasms, Breast","enrollment":66},{"nctId":"NCT02909751","phase":"PHASE2","title":"Tocotrienol in Combination With Neoadjuvant Chemotherapy for Women With Breast Cancer","status":"COMPLETED","sponsor":"Vejle Hospital","startDate":"2016-09-14","conditions":"Breast Cancer","enrollment":80},{"nctId":"NCT03983538","phase":"","title":"Mathematical Modeling to Predict Response to Neoadjuvant Chemotherapy in Breast Cancer","status":"COMPLETED","sponsor":"New Mexico Cancer Research Alliance","startDate":"2015-06-02","conditions":"Breast Cancer","enrollment":10},{"nctId":"NCT02324088","phase":"PHASE3","title":"Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2000-10","conditions":"Inflammatory Breast Cancer","enrollment":174},{"nctId":"NCT01690702","phase":"PHASE3","title":"Study of Nab-Paclitaxel in High Risk Early Breast Cancer","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2012-09","conditions":"Breast Cancer","enrollment":2886},{"nctId":"NCT00625898","phase":"PHASE3","title":"BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab","status":"TERMINATED","sponsor":"NSABP Foundation Inc","startDate":"2008-04","conditions":"Breast Cancer","enrollment":3509},{"nctId":"NCT02568839","phase":"PHASE2, PHASE3","title":"Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thomas Hatschek","startDate":"2014-11","conditions":"Early-Stage Breast Carcinoma, HER-2 Positive Breast Cancer","enrollment":202},{"nctId":"NCT03140553","phase":"PHASE2","title":"TCH Versus EC-TH as Neoadjuvant Treatment for HER2-Positive Breast Cancer","status":"COMPLETED","sponsor":"Guangdong Provincial People's Hospital","startDate":"2016-09-01","conditions":"HER2-Positive Breast Cancer","enrollment":140},{"nctId":"NCT01314833","phase":"PHASE3","title":"Minus Anthracycline or Short-Term Versus Epirubicin and Cyclophosphamide Followed by Paclitaxel Regimen for Adjuvant Breast Cancer Therapy","status":"COMPLETED","sponsor":"Fudan University","startDate":"2010-06-01","conditions":"Primary Breast Cancer","enrollment":1570},{"nctId":"NCT01216111","phase":"PHASE3","title":"Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN)","status":"COMPLETED","sponsor":"Fudan University","startDate":"2011-01-01","conditions":"Triple Negative Breast Cancer","enrollment":647},{"nctId":"NCT02532400","phase":"PHASE3","title":"Neoadjuvant Aromatase Inhibitor(AI) With Ovarian Suppression Versus Chemotherapy in Premenopausal Breast Cancer Patients","status":"TERMINATED","sponsor":"Ruijin Hospital","startDate":"2016-03","conditions":"Breast Cancer","enrollment":21},{"nctId":"NCT04127019","phase":"PHASE3","title":"Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER)","status":"COMPLETED","sponsor":"Fudan University","startDate":"2010-06-01","conditions":"Primary Breast Cancer","enrollment":2079},{"nctId":"NCT03785704","phase":"PHASE2","title":"Clinical Study of Xinmailong Injection on Reducing Cardiovascular Toxicity in Adjuvant Chemotherapy in Breast Cancer","status":"UNKNOWN","sponsor":"Peking Union Medical College","startDate":"2019-01-01","conditions":"Breast Neoplasms, Cardiac Event, Chemotherapeutic Toxicity","enrollment":60},{"nctId":"NCT00820547","phase":"PHASE2","title":"Efficacy and Tolerance Study of Bevacizumab in Her2- Inflammatory Breast Cancer Patients","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2009-01","conditions":"Breast Cancer","enrollment":100},{"nctId":"NCT02115204","phase":"PHASE3","title":"4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF","status":"COMPLETED","sponsor":"West German Study Group","startDate":"2000-06","conditions":"Breast Cancer","enrollment":2011},{"nctId":"NCT01869192","phase":"PHASE2","title":"Phase II Trial for Large ER-Negative Breast Cancers","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2003-03-05","conditions":"Malignant Neoplasm of Female Breast","enrollment":72},{"nctId":"NCT04094896","phase":"PHASE2","title":"TCHP Versus EC -THP as Neoadjuvant Treatment for HER2-Positive Breast Cancer","status":"UNKNOWN","sponsor":"Guangdong Provincial People's Hospital","startDate":"2019-09-17","conditions":"HER2-Positive Breast Cancer","enrollment":200},{"nctId":"NCT03251768","phase":"PHASE2","title":"Recombinant Human Serum Albumin/Granulocyte Colony Stimulating Factor Fusion Protein for Breast Cancer Patients","status":"COMPLETED","sponsor":"Tianjin SinoBiotech Ltd.","startDate":"2017-10-19","conditions":"Chemotherapy-induced Neutropenia","enrollment":80},{"nctId":"NCT01049425","phase":"PHASE3","title":"Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer","status":"COMPLETED","sponsor":"West German Study Group","startDate":"2009-02-05","conditions":"Primary Breast Cancer, Her2 Non-overexpressing","enrollment":3198},{"nctId":"NCT01907529","phase":"PHASE2, PHASE3","title":"A Trail of Neoadjuvant Endostar in Combination With Chemotherapy in Breast Cancer","status":"UNKNOWN","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2019-08","conditions":"Stage III Breast Cancer","enrollment":300},{"nctId":"NCT03123770","phase":"PHASE4","title":"Efficacy and Safety of Neoadjuvant DC-T in Breast Cancer Patients","status":"UNKNOWN","sponsor":"Zhejiang University","startDate":"2016-12","conditions":"Breast Cancer","enrollment":384},{"nctId":"NCT01690325","phase":"PHASE2","title":"Imaging for Response Assessment of Neoadjuvant Chemotherapy in Primary Breast Cancer (GALADON)","status":"TERMINATED","sponsor":"West German Study Group","startDate":"2012-09","conditions":"Breast Cancer","enrollment":21},{"nctId":"NCT01190345","phase":"PHASE2","title":"Anti Cancer Stem Cell Activity of Pre-operative Bevacizumab and Chemotherapy in Breast Cancer","status":"COMPLETED","sponsor":"Institut Paoli-Calmettes","startDate":"2010-05","conditions":"Breast Cancer","enrollment":75},{"nctId":"NCT01501487","phase":"PHASE4","title":"MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I","status":"COMPLETED","sponsor":"Agendia","startDate":"2011-10","conditions":"Breast Cancer","enrollment":226},{"nctId":"NCT00689156","phase":"PHASE3","title":"Epirubicin or Not in Patients With TOP2A (Topoisomerase (DNA) II Alpha (170kD)) Normal Early Breast Cancer","status":"COMPLETED","sponsor":"Danish Breast Cancer Cooperative Group","startDate":"2008-06","conditions":"Breast Neoplasms","enrollment":2015},{"nctId":"NCT00950300","phase":"PHASE3","title":"A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-10-16","conditions":"Breast Cancer","enrollment":596},{"nctId":"NCT03373708","phase":"PHASE2, PHASE3","title":"Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer","status":"UNKNOWN","sponsor":"Zhiyong Yu","startDate":"2017-12-20","conditions":"Breast Cancer, Chemotherapy, Endocrine Breast Diseases","enrollment":200},{"nctId":"NCT03349177","phase":"PHASE2, PHASE3","title":"Pathological Complete Response Rate in Locally Advanced Breast Cancer With FEC, EC-T, or TC as Neoadjuvant Chemotherapy","status":"UNKNOWN","sponsor":"Zhiyong Yu","startDate":"2017-11-27","conditions":"Breast Cancer, Pathological Complete Response, Neoadjuvant Chemotherapy","enrollment":200},{"nctId":"NCT02980965","phase":"PHASE3","title":"Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer","status":"COMPLETED","sponsor":"Fudan University","startDate":"2013-05","conditions":"Breast Cancer Female","enrollment":249},{"nctId":"NCT03085368","phase":"PHASE2, PHASE3","title":"A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2017-03-01","conditions":"HER2-positive Breast Cancer","enrollment":482}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ellence","Taxotere"],"phase":"phase_3","status":"active","brandName":"Epirubicin, cyclophosphamide and docetaxel","genericName":"Epirubicin, cyclophosphamide and docetaxel","companyName":"Danish Breast Cancer Cooperative Group","companyId":"danish-breast-cancer-cooperative-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a combination chemotherapy regimen that uses three cytotoxic agents to damage cancer cell DNA and inhibit cell division, used in breast cancer treatment. Used for Breast cancer (neoadjuvant and adjuvant treatment).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}